Theseus Pharmaceuticals Raises $100M in Series B Funding

21 Apr, 2021

Theseus Pharmaceuticals Raises $100M in Series B Funding
Photo by Alejandro Escamilla on Unsplash

– Theseus Pharmaceuticals from Boston develops pan-variant kinase inhibitors to treat cancer.
– The company emerged from stealth with the close of a $100m Series B financing.
– The round was led by Foresite Capital with participation from Adage Capital Management, Boxer Capital, Farallon Capital Management, Longitude Capital, Nextech Ventures, Omega Healthcare Investors, Pontifax Venture Capital, Rock Springs Capital, and T. Rowe Price, as well as OrbiMed.
– In conjunction with the financing, Michael Rome, Ph.D., Managing Director of Foresite Capital, has joined the Theseus Board of Directors.

Biotechnology Health Care Information Technology North America Pharmaceutical Travel
Crunchbase icon

Content report

The following text will be sent to our editors: